screen
potenti
convalesc
plasma
donor
cohort
patient
acut
respiratori
ill
suspect
merscov
confirm
realtim
revers
transcript
pcr
rrtpcr
upper
lower
respiratori
secret
healthcar
worker
expos
laboratoryconfirm
merscov
patient
identifi
ongo
activ
surveil
hospit
infect
prevent
control
depart
household
contact
patient
laboratoryconfirm
merscov
infect
obtain
written
inform
consent
merscov
serolog
test
healthcar
worker
household
contact
medic
team
order
serolog
test
part
clinic
care
patient
suspect
confirm
merscov
infect
addit
inform
consent
requir
healthcar
worker
complet
selfadminist
survey
ask
question
natur
durat
degre
exposur
patient
laboratoryconfirm
merscov
infect
studi
particip
document
time
elaps
symptom
onset
exposur
collect
sampl
test
screen
serum
sampl
studi
particip
use
spike
protein
subunit
elisa
confirm
result
elisareact
sampl
use
indirect
immunofluoresc
antibodi
ifa
microneutr
mn
assay
merscov
patient
nonreact
elisa
result
collect
followup
sampl
day
later
repeat
elisa
studi
particip
consid
candid
plasma
donat
reactiv
elisa
result
mn
assay
titer
clinic
laboratori
evid
ongo
merscov
infect
met
elig
plasma
donat
accord
institut
criteria
accord
guidelin
person
met
criteria
elig
plasma
donat
accord
posit
paper
blood
regul
network
primari
outcom
first
phase
studi
feasibl
conduct
second
phase
feasibl
measur
abil
screen
identifi
suffici
number
potenti
plasma
donor
provid
enough
hightit
freshfrozen
plasma
enrol
provid
transfus
patient
month
phase
patient
would
requir
freshfrozen
plasma
unit
mlunit
first
conduct
test
merscov
rrtpcr
extract
rna
respiratori
specimen
nasopharyng
swab
tracheal
aspir
bronchoalveolar
lavag
use
magna
pure
viral
na
kit
roch
appli
scienc
indianapoli
usa
test
extract
nucleic
acid
rrtpcr
target
upstream
envelop
protein
gene
upe
openread
frame
region
merscov
genom
lightcycl
system
roch
diagnost
mannheim
germani
realtim
pcr
posit
control
upe
rrtpcr
perform
accord
manufactur
instruct
consist
cutoff
use
saudi
arabia
ministri
health
refer
laboratori
consid
cycl
threshold
ct
cutoff
upe
ct
repeat
test
use
differ
sampl
prefer
lower
respiratori
tract
avoid
falseposit
result
detect
merscov
antibodi
elisa
euroimmun
ag
lubeck
germani
use
well
coat
merscov
antigen
serum
sampl
dilut
incub
antigen
accord
elisa
manufactur
instruct
posit
neg
control
serum
calibr
sampl
includ
antibodi
detect
ad
peroxidaselabel
rabbit
igg
euroimmun
ag
lubeck
result
report
optic
densiti
od
ratio
calcul
od
valu
patient
sampl
divid
calibr
od
valu
use
cutoff
valu
recommend
elisa
kit
manufactur
ratio
consid
neg
consid
borderlin
consid
posit
use
ifa
euroimmun
ag
accord
manufactur
instruct
detect
merscov
antibodi
serum
sampl
dilut
doubl
dilut
start
end
sampl
buffer
incub
vero
cell
infect
hcovemc
euroimmun
ag
merscov
igg
detect
ad
fitclabel
goat
igg
euroimmun
ag
posit
neg
control
includ
sampl
ifa
titer
consid
reactiv
accord
ifa
manufactur
instruct
origin
protocol
use
ifa
cutoff
defin
suitabl
donor
plasma
cours
studi
mn
becam
avail
revis
criteria
plasma
donat
base
mn
assay
result
presenc
neutral
merscov
antibodi
also
assess
use
mn
assay
brief
vero
cellswel
plate
onto
microtit
plate
h
serial
dilut
serum
sampl
heatinactiv
min
incub
equal
volum
merscov
strain
tissu
cultur
infecti
dose
h
medium
aspir
microtit
plate
mixtur
ad
well
triplic
plate
incub
h
humidifi
chamber
carbon
dioxid
mixtur
aspir
cell
fix
ad
mixtur
cold
ethanol
methanol
plate
incub
min
wash
time
pb
process
describ
elisa
use
rabbit
spike
protein
antibodi
horseradish
goat
igg
secondari
antibodi
plate
develop
use
abt
substrat
kpl
inc
gaithersburg
md
usa
od
measur
nm
control
consist
uninfect
cell
cell
infect
merscov
highest
dilut
serum
sampl
result
reduct
od
compar
control
contain
antibodi
report
viru
neutral
titer
rrtpcr
elisa
ifa
test
merscov
perform
king
abdulaziz
medic
citi
laboratori
mn
perform
naval
medic
research
center
silver
spring
md
usa
use
descript
statist
ie
number
proport
mean
sd
median
quartil
valu
measur
elig
donor
particip
seroreact
test
result
use
pearson
correl
test
correl
elisa
od
ifa
mn
titer
ident
studi
particip
merscov
known
investig
list
approv
king
abdullah
intern
medic
research
center
protocol
sampl
delink
identifi
person
inform
provid
nonlist
investig
contact
healthcar
worker
histori
exposur
diagnosi
merscov
infect
healthcar
worker
consent
serum
sampl
test
tabl
histori
laboratoryconfirm
merscov
infect
histori
exposur
merscov
rrtpcr
neg
asymptomat
potenti
immedi
postincub
period
healthcar
worker
histori
laboratoryconfirm
merscov
infect
elisareact
serum
sampl
median
day
day
day
infect
figur
confirmatori
ifa
reactiv
healthcar
worker
mn
reactiv
tabl
howev
healthcar
worker
particip
high
mn
titer
tabl
consid
candid
plasma
donat
previou
pregnanc
expos
healthcar
worker
neg
merscov
rrtpcr
result
also
nonreact
elisa
result
total
patient
suspect
laboratoryconfirm
merscov
infect
test
hospit
emerg
depart
intens
care
unit
medic
ward
tabl
two
patient
laboratoryconfirm
merscov
merscov
rrtpcr
neg
elisareact
serum
sampl
ifa
mn
assay
result
posit
patient
elisareact
serum
sampl
patient
nonreact
ifa
result
also
nonreact
mn
result
one
patient
high
ifa
mn
titer
tabl
patient
man
admit
intens
care
unit
merscov
infect
result
acut
respiratori
distress
syndrom
acut
kidney
injuri
shock
requir
mechan
ventil
renal
replac
therapi
vasopressor
figur
high
titer
occur
intens
care
day
symptom
onset
serolog
titer
elisa
ifa
mn
declin
progress
recov
clinic
elisa
ifa
nonreact
month
hospit
admiss
figur
patient
no
mn
titer
tabl
patient
meet
clinic
criteria
plasma
donat
age
concurr
condit
previou
pregnanc
note
patient
laboratoryconfirm
merscov
infect
nonreact
elisa
sampl
collect
day
symptom
onset
two
patient
die
test
repeat
third
patient
repeat
elisa
week
first
nonreact
elisa
neg
median
day
day
day
patient
receiv
laboratori
diagnosi
merscov
infect
test
household
contact
patient
tabl
serum
sampl
contact
nonreact
elisa
figur
tabl
elisa
mn
result
highli
correl
pearson
correl
coeffici
p
figur
howev
elisa
ifa
result
show
modest
correl
pearson
correl
coeffici
p
ifa
mn
result
statist
significantli
correl
pearson
correl
coeffici
p
result
indic
would
possibl
obtain
quantiti
convalesc
plasma
larg
enough
use
therapeut
studi
larg
number
merscov
patient
howev
largescal
screen
would
requir
limit
avail
elig
potenti
donor
suffici
level
antibodi
find
suggest
recent
recov
mer
patient
may
suitabl
potenti
donor
provid
meet
plasma
donat
criteria
note
none
seroposit
person
studi
met
clinic
laboratori
criteria
plasma
donat
find
show
serum
antibodi
merscov
infrequ
reactiv
elisa
howev
reactiv
may
affect
time
sampl
collect
sever
ill
small
subset
particip
elisareact
serum
sampl
merscov
antibodi
assess
ifa
mn
elisa
result
mn
titer
highli
correl
ifa
mn
one
healthcar
worker
high
mn
titer
meet
clinic
criteria
plasma
donat
anoth
critic
ill
patient
high
antibodi
titer
assay
antibodi
titer
declin
quickli
patient
recov
clinic
elig
donat
plasma
accord
us
center
diseas
control
prevent
guidelin
use
elisa
screen
merscov
igg
ifa
mn
assay
confirm
posit
result
elisa
base
viru
protein
antigen
ifa
base
detect
virusspecif
antibodi
use
cell
cultur
infect
viru
merscov
spike
protein
glycoprotein
form
spike
viru
n
termin
compon
believ
respons
first
step
viru
entri
host
cell
origin
protocol
use
ifa
confirmatori
test
howev
switch
mn
assay
becam
avail
find
show
high
correl
elisa
mn
result
ifa
mn
result
may
indic
mn
better
confirmatori
test
howev
patient
studi
test
show
similar
result
figur
studi
shown
good
correl
test
may
indic
lack
correl
shown
ifa
mn
studi
associ
sampl
size
find
suggest
low
preval
seroreact
merscov
even
among
person
confirm
suspect
infect
may
reflect
shortlast
antibodi
respons
possibl
studi
particip
seroneg
time
test
window
posit
serolog
result
pass
shortlast
immun
respons
may
also
partli
explain
neglig
low
level
merscov
seroreact
detect
person
risk
diseas
ie
camel
abattoir
worker
saudi
arabia
elsewher
seropreval
studi
conduct
decemb
show
merscov
antibodi
gener
popul
n
provinc
saudi
arabia
seropreval
also
low
among
camel
shepherd
n
slaughterhous
worker
n
albeit
higher
gener
popul
clinic
relev
antibodi
titer
protect
subsequ
merscov
infect
uncertain
similar
find
describ
coronavirus
cao
et
al
studi
specif
neutral
antibodi
titer
patient
recov
sarscov
infect
find
show
sarscov
igg
neutral
antibodi
peak
month
began
diminish
reach
undetect
level
igg
neutral
antibodi
patient
month
xie
et
al
show
sarscov
igg
decreas
year
recov
sar
patient
experi
intranas
inocul
cov
human
volunt
callow
et
al
studi
time
cours
specif
antibodi
respons
found
antibodi
peak
week
inocul
began
declin
furthermor
appear
antibodi
immun
respons
merscov
human
differ
camel
alagaili
et
al
show
camel
differ
part
saudi
arabia
antibodi
merscov
elisa
preval
antibodi
higher
older
camel
two
patient
merscov
outbreak
south
korea
report
receiv
convalesc
plasma
collect
recov
patient
unclear
whether
plasma
test
presenc
merscov
antibodi
studi
demonstr
test
mandatori
donat
convalesc
plasma
low
preval
merscov
antibodi
even
patient
past
laboratoryconfirm
merscov
infect
without
test
presenc
antibodi
merscov
confirm
convalesc
plasma
may
associ
protect
effect
studi
also
highlight
need
prospect
serolog
studi
better
understand
humor
respons
merscov
infect
strength
studi
screen
larg
number
person
includ
patient
laboratoryconfirm
merscov
infect
use
screen
confirmatori
antibodi
assay
studi
limit
small
number
household
contact
screen
although
base
find
other
small
proport
household
contact
like
show
seroreact
one
third
invit
healthcar
worker
particip
studi
use
elisa
screen
studi
address
magnitud
durat
antibodi
isotyp
immun
respons
interv
ill
recoveri
prolong
expos
healthcar
worker
median
interv
year
possibl
earlier
sampl
would
result
detect
reactiv
higher
antibodi
titer
studi
design
screen
antibodi
convalesc
plasma
design
character
immun
respons
merscov
infect
identifi
clinic
correl
presenc
absenc
merscov
antibodi
test
need
determin
whether
antibodi
convalesc
plasma
clinic
effect
merscov
infect
find
suggest
need
explor
passiv
immunotherapeut
approach
monoclon
polyclon
human
antibodi
transchromosom
bovin
possibl
polyclon
antibodi
camel
find
also
rais
question
whether
natur
occur
infect
potenti
merscov
vaccin
offer
longlast
immun
